Fennec Pharmaceuticals Stock Performance
| FENC Stock | USD 4.72 0.08 1.72% |
The firm shows a Beta (market volatility) of 1.43, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fennec Pharmaceuticals will likely underperform. At this point, Fennec Pharmaceuticals has a negative expected return of -0.25%. Please make sure to confirm Fennec Pharmaceuticals' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Fennec Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fennec Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 15.66 | Five Day Return 23.53 | Year To Date Return (50.90) | Ten Year Return 112.7 | All Time Return 76.7 |
Last Split Factor 1:3 | Last Split Date 2014-09-05 |
1 | Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Raykov Rosty of 2431 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | 09/30/2024 |
3 | Insider Sale Director Rosty Raykov Sells Shares of Fennec Pharmaceuticals Inc | 10/02/2024 |
4 | Acquisition by Robert Andrade of 1042 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | 10/31/2024 |
5 | Disposition of 2431 shares by Raykov Rosty of Fennec Pharmaceuticals at 4.31 subject to Rule 16b-3 | 11/04/2024 |
6 | Fennec Pharmaceuticals Inc. Q3 2024 Earnings Call Transcript | 11/11/2024 |
7 | Fennec Pharmaceuticals Drops To US4.26, Yet Insiders May Have Sold Too Early | 11/12/2024 |
8 | Acquisition by Sayad Pierre Sargis of 150000 shares of Fennec Pharmaceuticals at 4.23 subject to Rule 16b-3 | 11/13/2024 |
9 | Acquisition by Robert Andrade of 15816 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3 | 11/18/2024 |
| Begin Period Cash Flow | 23.8 M |
Fennec |
Fennec Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 584.00 in Fennec Pharmaceuticals on August 24, 2024 and sell it today you would lose (112.00) from holding Fennec Pharmaceuticals or give up 19.18% of portfolio value over 90 days. Fennec Pharmaceuticals is currently does not generate positive expected returns and assumes 3.9687% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Fennec, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fennec Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fennec Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fennec Pharmaceuticals, and traders can use it to determine the average amount a Fennec Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0641
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FENC |
Estimated Market Risk
| 3.97 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fennec Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fennec Pharmaceuticals by adding Fennec Pharmaceuticals to a well-diversified portfolio.
Fennec Pharmaceuticals Fundamentals Growth
Fennec Stock prices reflect investors' perceptions of the future prospects and financial health of Fennec Pharmaceuticals, and Fennec Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fennec Stock performance.
| Return On Equity | -10.06 | ||||
| Return On Asset | 0.027 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 121.15 M | ||||
| Shares Outstanding | 27.43 M | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 2.62 X | ||||
| Revenue | 21.25 M | ||||
| Gross Profit | 1.45 M | ||||
| EBITDA | (12.36 M) | ||||
| Net Income | (16.05 M) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 30.95 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (17.14 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Market Capitalization | 129.48 M | ||||
| Total Asset | 26.86 M | ||||
| Retained Earnings | (219.25 M) | ||||
| Working Capital | 19.3 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
About Fennec Pharmaceuticals Performance
By analyzing Fennec Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Fennec Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fennec Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fennec Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 625.05 | 818.58 | |
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.66) | (0.63) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | 1.38 | 1.45 |
Things to note about Fennec Pharmaceuticals performance evaluation
Checking the ongoing alerts about Fennec Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fennec Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fennec Pharmaceuticals generated a negative expected return over the last 90 days | |
| Fennec Pharmaceuticals has high historical volatility and very poor performance | |
| Fennec Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 21.25 M. Net Loss for the year was (16.05 M) with profit before overhead, payroll, taxes, and interest of 1.45 M. | |
| Fennec Pharmaceuticals currently holds about 14.91 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57. | |
| Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 |
- Analyzing Fennec Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fennec Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Fennec Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fennec Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fennec Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fennec Pharmaceuticals' stock. These opinions can provide insight into Fennec Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |